Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Company Data

Name Neuphoria Therapeutics Inc. - Common Stock

Company Neuphoria Therapeutics Inc.

Symbol NEUP

Website http://www.neuphoriatx.com

Primary Exchange

NASDAQ

ISIN US64136E1029

Asset Class Share

Sector Healthcare

Industry Medical - Pharmaceuticals

CEO Spyridon Papapetropoulos

Market Capitalization 14 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 100 Summit Dr, Burlington

IPO Date 2021-12-16

ID Changes

Date	From	To
24.12.2024	BNOX	NEUP

Ticker Symbols

Name	Symbol
NASDAQ	NEUP

More Shares

Investors who hold Neuphoria Therapeutics Inc. - Common Stock also have the following shares in their portfolio:

Independent Invest II - Independent Generations Fund Fund

MORGAN STANLEY 3.24% NTS 14/12/22 Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog